Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$1.05
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $126.4M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
6.6x
↓EV/EBITDA
1.3x
↓ROE
6.3%
↑Gross Margin
49.7%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.2%
FCF CAGR
+4.2%
FCF margin
19.2%
FCF / Net income
1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.23B · net income $214.0M · FCF $236.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.23B | $1.23B | $1.06B | $1.15B | $1.28B |
| Net Income | $214.0M | $214.0M | $564.9M | $326.0M | $358.1M |
| EBITDA | $370.3M | $370.3M | $747.2M | $498.9M | $505.2M |
| EPS | 0.14 | 0.14 | 0.38 | 0.22 | 0.24 |
| Gross Margin | 49.7% | 49.7% | 54.5% | 55.7% | 60.5% |
| Operating Margin | 24.5% | 24.5% | 34.7% | 38.4% | 35.1% |
| Net Margin | 17.4% | 17.4% | 53.3% | 28.3% | 28.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.01 | 0.04 | 0.00 |
| Current Ratio | 4.64 | 4.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $236.0M | $236.0M | $44.6M | $126.4M | $208.6M |
| Returns | |||||
| ROE | 6.3% | 6.3% | 17.0% | 11.4% | 13.6% |
| Valuation | |||||
| P/E | 6.56 | 6.56 | 3.20 | 5.12 | 5.41 |
| EV/EBITDA | 1.32 | 1.32 | 0.91 | 1.77 | 2.25 |
| P/B | 0.47 | 0.47 | 0.54 | 0.58 | 0.73 |
| Growth & Yield | |||||
| Revenue Growth | 16.1% | 16.1% | -7.9% | -9.9% | — |
| EPS Growth | -62.7% | -62.7% | 72.9% | -8.9% | — |
| Dividend Yield | 6.0% | 6.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-12.7%
EPS terminal req.
$0.09
Spread vs growth
-50.0%
5Y implied EPS CAGR
-4.2%
EPS terminal req.
$0.11
Spread vs growth
-58.4%
10Y implied EPS CAGR
2.6%
EPS terminal req.
$0.18
Spread vs growth
-65.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.5%
Start / end P/E
3.2x → 7.5x
EPS bridge
0.38 → 0.14
Residual
-84.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.